page 2019 kasbp spring symposium spring symposium/20… · president sean kim 김승빈 lueprint...

1 | P a g e 2 0 1 9 K A S B P S p r i n g S y m p o s i u m


Welcoming Letter to 2019 KASBP Spring Symposium

Korean American Society in Biotech and Pharmaceuticals (KASBP) cordially invites you to the “2019 KASBP Spring Symposium” in New Jersey from May 31 to June 1, 2019. This symposium is co-hosted by Hanmi, Yuhan, GC Pharma and SK Biopharmaceuticals and was supported by generous financial supports from our sponsors. The main theme for this year’s Spring Symposium is “Drug Discovery and Development – From Bench to Commercialization”. The symposium organizing committee has invited six outstanding speakers from both academia and pharmaceutical industry, who will share their experience and expertise with the audience. It will be delightful to hear about cutting-edge sciences in COPD pathogenesis, cannabis research and SK R&D as well as advances in protein degrader, anti-sense oligonucleotide, and LBA technology. We are also delighted to

announce Dr. Young-Choon Moon, Vice President at PTC Therapeutics as our distinguished keynote speaker. Dr. Moon is the head of chemistry at PTC he led successful development of Translarna and Risdiplam. This year, KASBP will have a special recognition for Dr. Sechang Kwon, President Hanmi Pharmaceutical, as the recipient of “KASBP Appreciation Award” for his long-standing contribution to pharmaceutical science and the growth of KASBP. We also would like to congratulate ten awardees who were selected for KASBP-Hanmi, KASBP-GC Pharma, KASBP-Yuhan, and KASBP-SKBP Fellowships. Your dedication to the advancement of life-science research inspire us.

Job fair also became a long tradition of KASBP symposium program and many qualified applicants will have an opportunity to interview with prominent Korean pharmaceutical and biotechnology companies. On Saturday evening, an optional special session will be held under the theme of “IND: Regulatory Path and Content”. The session will be led by distinguished panelists from the fields of Regulatory Affair, DMPK and Drug Safety. With these exciting topics and themes, the symposium organizing committee is looking forward to meeting all members and friends in New Jersey!

2018-2019 KASBP President 2019 KASBP Spring Symposium Program Chair

Sean Kim, PhD Wooseok Han, PhD


2018 – 2019 KASBP OFFICERS

Title Name 한글 이름 Affiliation

President Sean Kim 김승빈 Blueprint Medicines

President Designated K. Stephen Suh 서광순 DiagnoCine

1st Vice President Mooje Sung 성무제 Novartis

Executive Director Wooseok Han 한우석 Novartis

Science Director Hyun-Hee Lee 이현희 Merck

Financial Director Sahee Kim 김사희 RevHealth, LLC

Web Director DaeHo Lee 이대호 Express Care Pharmacy

Human Resource Director Dooyoung Lee 이두영 Morphic Therapeutic

Member Networking Director Claire Jeong Sandy Suh

정가영

서샌디

GSK Exeltis USA

Membership Director So Hyun (Aria) Rhee

Jiyoung Park

이소현

박지영

Rutgers University Golden Healthcare Pharmacy

Public Relations Director Hyunjin Shin 신현진 Takeda

YG Director Ji Eun Lee 이지은 MCPHS

Legal Director Elizabeth Lee 이엘리자베스 Lucas & Mercanti

NJ Chapter President Youngsun Kim 김영선 Adello Biologics

Boston Chapter President Soo-Hee Park 박수희 Novartis

Connecticut Chapter President

Sung-Kwon Kim 김성권 Alexion

Philadelphia Chapter President

Younghoon Oh 오영훈 Spark Therapeutics

San Francisco Chapter President

Hanjo Lim 임한조 Genentech

Washington DC Chapter President

Nam Cheol Kim 김남철 United States Pharmacopeia

Illinois Chapter President Seungwon Chung 정승원 AbbVie

Councilor – Finance/legal Yun H. Choe 최윤 Lucas & Mercanti

Councilor - Grant Hak-Myung Lee 이학명 Shire

Councilor - Auditing Sungtaek Lim 임성택 Sanofi

Councilor - Outreach Yun H. Choe 최윤 Lucas & Mercanti

Councilor – Chair, Advisory Committee

Jae Uk Jeong 정재욱 GSK

Advisory Committee Past KASBP Presidents


2019 KASBP Spring Symposium Committee

Symposium

Committee Chair Members

Program Committee Wooseok Han

Jae Uk Jeong, Sung-Kwon Kim, Hanjo Lim

Registration Committee Sungki Kim Ji Eun Lee, Melody Park, Hyun-jun Kim, Hye-lim Kim, Ji-min

Son, Joo-hae Kim, Yun Choe

Fellowship Committee Hyun-Hee Lee /

Jennie Jung

KiBum Lee, Hakryul Jo, Mooje Sung, Youngsun Kim

Job Fair Committee Dooyoung Lee Melody Park, Hyunjun Kim

Finance Committee Sahee Kim Yun H. Choe, Youngsun Kim

PR Committee Hyunjin (Gene)

Shin Sean Kim

Graphic Design Jamie Jiyoung Park

On-line Registration and

Web Master Daeho Lee


Symposium Schedule at a Glance

May 31 (Friday) June 1 (Saturday)

AM 7

Arrival and Check-in

7:30 – 8:30 AM Registration and Breakfast

8 8:30 – 8:45 AM Opening Remarks

8:45 – 10:45 AM Scientific Session A

9

10

10:45 –11:00 AM Coffee Break

11 11:00 – 12:15 PM Fellowship Awards Ceremony

PM 12 12:15 – 12:30 PM Group Photo

12:30 – 2:00 PM Lunch and Poster Session

1

2 2:00 – 3:00 PM Sponsor Presentation

3 3:00-5:30 PM Job Fair 3:00 – 3:15 PM Coffee Break

3:15 – 5:15 PM Scientific Session B

4

5 5:15 – 5:30 PM Scientific Session Closing

Remarks and Break

5:30 – 6:30 PM Registration and

Networking

5:30 – 7:30 PM Dinner and Panel Discussion

(registration required) 6

6:30 – 7:30 PM Opening &Congratulatory

Remarks and Dinner 7

7:30 – 8:00 PM Award Ceremony 7:30 – 8:00 PM Symposium Closing Remarks

8 8:00 – 9:00 PM Keynote Presentation

Have safe trip back home and See you again in the

next symposium!

9 9:00 – 9:10 PM Mentor-Mentee Program

9:10 – 10:00 PM Networking Session

10 10:00 PM - Free Networking


Symposium Schedule in Detail

May 31, 2019 Friday

Job Fair

3:00 pm ~ 5:30 pm KASBP HR Director, Dooyoung Lee, Morphic Therapeutic

Registration & Networking

5:30 pm ~ 6:30 pm Registration Team

Opening & Congratulatory Remarks and Dinner

6:30 pm ~ 7:30 pm Moderator: Wooseok Han, KASBP Executive Director, Novartis

• Opening Remark KASBP President, Sean Kim, Blueprint Medicines

• Congratulatory Remarks

• Prosperity Toast

• Dinner

Award Ceremony Introduction: Sung Mooje, KASBP Vice President, Novartis

7:30 pm ~ 8:00 pm KASBP Appreciation Award

Awardee: Sechang Kwon, President, Hanmi Pharmaceutical

Keynote Lecture Introduction: Wooseok Han, KASBP Executive Director, Novartis

8:00 pm ~ 9:00 pm RNA Targeting Drug Discovery

Young-Choon Moon, Vice President, PTC Therapeutics

Networking Session

9:00 pm ~ 9:10 pm Mentor-Mentee Program

KASBP YG Director, Ji Eun Lee, MCPHS

9:10 pm ~ 10:00 pm Networking

KASBP President-designate, K. Stephen Suh, DiagnoCine

Moderator

Biology Immuno-oncology/Autoimmune/Inflammatory Kern Chang Respiratory/Metabolic/Cardiovascular/Aging/Mental/Neurogenerative Soo-Hee Park Cell and Gene Therapy/Viral infection/Rare disease Hakryul Jo Chemistry Seungwon Chung PK/PD/pre-clinical/Clinical Science Hanjo Lim BD/Legal/VC Yun H Choe Pharmacy Pharmacy Students can join any group


June 1, 2019 Saturday

Registration & Breakfast

7:30 am ~ 8:30 am

Opening Remarks

8:30 am ~ 8:45 am KASBP President-designate, K. Stephen Suh, DiagnoCine

Scientific Session A

8:45 am ~ 10:45 am Chair: KASBP-Philadelphia Chapter President, Yonghoon Oh, Spark Therapeutics

• A-1: A Mitochondrial Perspective of COPD Pathogenesis – Focusing on Mitochondrial

Innate Immunity

Min-Jong Kang, Yale University School of Medicine

• A-2: SK Biopharmaceuticals: From R&D to Commercialization

Jeong Woo Cho, SK Biopharmaceuticals

• A-3: New Frontier: Science of Endocannabinoid and Cannabis Research in Drug Development

Dennis Kim, Emerald Health Services

Coffee Break

10:45 am ~ 11:00 am

Fellowship Award Ceremony

11:00 am ~ 12:15 pm KASBP Science Director, Hyun-Hee Lee, Merck

Group Photo time

12:15 pm ~ 12:30 pm

Lunch & Poster Presentation

12:30 pm ~ 2:00 pm


Sponsor Presentation

2:00 pm ~ 3:00 pm Chair: Connecticut Chapter President, Sung-Kwon Kim, Alexion

• Introduction to Yuhan R&D and Yuhan USA

Yoohoi Park, Director and Sungwoo Ahn, Project Manager

• Introduction to Hanmi Pharmaceuticals R&D

Young-Mi Lee, Executive Director, Head of Global External R&D Innovation

• Introduction of Bridge Biotherapeutics

Yong-Hee Lee, President, Bridge Biotherapeutics, USA and SVP, Head of Development

• Introduction of GC Pharma

Seungkwon Choi, Vice President, Human Resources

Coffee Break

3:00 pm ~ 3:15 pm

Scientific Session B

03:15 am ~ 05:15 pm Chair: Washington-DC Chapter President, Nam Chul Kim, United States

Pharmacopeia

• B-1: Current Progress on Protein Degradation Therapeutics

Hyunsun Jo, Pin Therapeutics

• B-2: Antisense Oligonucleotide Therapeutics for Difficult to Inhibit Drug Targets

Youngsoo Kim, Ionis Pharmaceuticals

• B-3: Critical Ligand-Binding Reagents for Robust Bioanalytical Assays: Characterization

and Lifecycle Management

Hanjo Lim, Genentech

Scientific Session Closing Remarks

5:15 pm ~ 05:30 pm KASBP President, Sean Kim, Blueprint Medicines

Dinner & Panel Discussion "IND: Regulatory Path and Content"

5:30 pm ~ 7:30 pm

• Dinner and Networking (30 min)

• Presentation (60 min)

Regulatory Affair – IND Sandy Suh, Exeltis USA

DMPK Deliverables in Support of IND Filing, Mi-Sook Kim, Takeda

Drug Safety Package to Enable IND Filing, Sean Kim, Blueprint Medicines

• Panel Discussion (30 min)


KEYNOTE LECTURE

ABSTRACT

RNA Targeting Drug Discovery

Young-Choon Moon, Ph.D.

Vice President, PTC Therapeutics

Biography

Dr. Young-Choon Moon currently serves as the vice president of PTC Therapeutics. Since joining PTC Therapeutics in 2002,

he has discovered and developed various RNA therapeutics including Translarna (PTC124), PTC299, PTC596, and Risdiplam

(RG7916, RO7034067). Prior to joining PTC, he worked as a scientist in Vertex Pharmaceuticals, LG Life Science, and Korea

Research Institute of Chemical Technology for more than 10 years. Upon earning his Ph.D. at University of Illinois, Dr. Moon

joined Prof. E. J. Corey’s laboratory for post-doctoral research at Harvard. He received B.S. in Chemistry and Trade from

Sogang University. Dr. Moon is a founding member of KASBP and has continuously served as president and council member

which have been instrumental in remarkable growth of KASBP.

Abstract

PTC Therapeutics is named for Post Transcriptional Control, and mRNA translation has been a focus of the company for

the past 21 years. We have utilized our GEMS™ (Gene Expression Modulation by Small Molecules) drug discovery platform

to identify small-molecules targeting RNA. I will present several examples of our approaches to successfully identify

compounds that target alternative splicing. I will also highlight our pipeline expansion and future direction for PTC.

KASBP Appreciation Award

Sechang Kwon, Ph.D., President, Hanmi Pharmaceutical Company

With Our Greatest

Appreciation

We Present

Sechang Kwon, Ph.D.

CEO, President

Hanmi Pharmaceutical Company

This Award In Recognition For

Outstanding Contribution To The Growth Of Korean Pharmaceutical Industry

And Inspiration To The Community Of Korean-American Scientists In Kasbp


SCIENTIFIC SESSION

ABSTRACTS

SESSION A

A-1: A Mitochondrial Perspective of COPD Pathogenesis – Focusing on Mitochondrial Innate Immunity

Min-Jong Kang, M.D., Ph.D.

Professor, Yale University School of Medicine

Biography

Dr. Min-Jong Kang is currently the Director of the Pulmonary Exposure Core at Yale and has active research programs in

basic and translational studies of pulmonary biology/medicine. His early studies demonstrated that the activation of

mitochondrial innate immune signaling plays an important role in the pathogenesis of chronic obstructive pulmonary

disease (COPD). Focusing on mitochondrial innate immune signaling, Dr. Kang's consecutive studies demonstrated that the

nucleotide-binding domain and leucine-rich-repeat-containing protein X1 (NLRX1), a novel mitochondrial molecule, plays

an important inhibitory role in the pathogenesis of COPD. As revealed in this track record, his laboratory has made

meaningful contributions to the advancement of pulmonary medicine/health by providing a better understanding of

mitochondrial damage associated molecular patterns (mitoDAMPs)/mitochondrial dysfunction, which may play a key role

in lung injury/damage responses and consequent pulmonary tissue remodeling pathologies. Dr. Kang earned his M.D.,

Ph.D., and M.P.H. at Seoul National University.

Abstract

Chronic obstructive pulmonary disease (COPD) encompasses several clinical syndromes, most notably emphysema and

chronic bronchitis. Most of the current treatments fail to attenuate severity and progression of the disease, thereby

requiring better mechanistic understandings of pathogenesis to develop disease-modifying therapeutics. A number of

theories on COPD pathogenesis have been promulgated wherein an increase in protease burden from chronic

inflammation, exaggerated production of ROS and the resulting oxidant injury, or superfluous cell death responses caused

by enhanced cellular injury/damage were proposed as the culprit. These hypotheses are not mutually exclusive and

together likely represent the multifaceted biological processes involved in COPD pathogenesis. As known, mitochondrial

function and behavior are fundamental to the physiology of cellular and organismal health, and thus, “mitochondrial

dysfunction” has been implicated in almost every aspect of human health and sickness. In accordance with this, recent

advancements on mitochondrial biology have enabled us to rethink of mitochondrial role in the pathogenesis of COPD and,

hopefully, to illuminate connections between mitochondrial and COPD that could unify multifaceted biological processes

and theories on COPD pathogenesis. These recent scientific advances are reviewed and integrated into a view of COPD

pathogenesis whereby mitochondria play a central role.

A-2: SK Biopharmaceuticals: From R&D to Commercialization

Jeong Woo Cho, Ph.D.

President & CEO, SK Biopharmaceuticals Co., Ltd. & SK Life Science, Inc.

Biography

Dr. Jeong Woo Cho is currently the president and CEO of SK Biopharmaceuticals and SK Life Science. He also served as Chief

Operating Officer (COO) and head of New Drug Business Division of SK Biopharmaceuticals till 2016. Under his leadership,

SK Bio discovered and successfully out-licensed Solriamfetol which was recently approved by FDA for treatment of


narcolepsy. SKBP is also independently conducting a clinical trial in US with Cenobamate for partial-onset seizures. Dr. Cho

earned his Ph.D. in Biology at the Texas A&M University, College Station, Texas.

Abstract

SK Biopharmaceuticals commenced research and development of new drugs in 1993 as part of our search for the next-

generation growth engine of SK Group. The exciting ascend of SK Biopharmaceuticals began with the acquisition of FDA

approval for clinical test for a new candidate drug substance in 1996. Currently, SK Biopharmaceuticals is conducting basic

research for the development of innovative new drugs at the Bio Science Research Institute in Pangyo, Gyeonggi Province.

Further, SK Life Science Inc. in Fair Lawn, New Jersey, USA, is pursuing global clinical development and direct marketing. In

addition, SK Bio-pharm Tech. Company, Ltd. in Shanghai, China is striving to secure opportunities for strategic alliances in

the development of new drugs. SK Biopharmaceuticals has been leading the development of new innovative drugs

targeting the global market. We aim to grow into a fully integrated global pharmaceutical company (global FIPCO),

equipped with the entire value chain ranging from development and manufacturing to commercialization via our own sales

and marketing organization.

A-3: New Frontier: Science of Endocannabinoid and Cannabis Research in Drug Development

Dennis Kim, M.D., M.B.A.

Chief Medical Officer, Emerald Health Services

Biography

Dr. Dennis Kim is a physician biotechnology executive with specialty training in endocrinology/metabolism spanning

approximately 20 years of drug/product development and corporate strategy experience in the biotech and medical

technology industries. Dr. Kim joined Emerald Health Sciences in March of 2019 as the company's Chief Medical Officer

and has taken a leadership development role across Emerald's portfolio of companies and also brings business

development experience. Prior to this he was Chief Medical Officer at Zafgen for 7.5 years where he oversaw all aspects of

clinical and medical affairs in the field of diabetes, obesity, and rare metabolic/genetic disorders. Prior to joining Zafgen,

Dr. Kim held multiple senior-level positions at Orexigen Therapeutics (Sr. VP of Medical and Clinical Affairs), EnteroMedics

(Chief Medical Officer) and Amylin Pharmaceuticals (Exec Director of Corporate Strategy). He holds an MD from the

University of Health Sciences, The Chicago Medical School, an MBA from UCSD Rady School of Management and a B.S. in

biology from the University of California at Los Angeles. His endocrinology/metabolism specialty fellow training was

completed at UCSD School of Medicine.

Abstract

Cannabis plants have been in existence for millions of years. Human use of cannabis, either for medicinal or recreational

purposes, has been documented for thousands of years. But it is only recently, during the 1990’s, that the endocannabinoid

system (ECS) has been described and endogenous receptors to different components of the cannabis identified. Replete

with social and political stigma and biases, we are at the precipice and inception of scientific pursuit and discovery of this

plant’s chemical, biological, and pharmacological properties and values. The ECS putatively has homeostatic function in

humans, with two major endogenous receptors – CB1 and CB2 – distributed ubiquitously and densely throughout most

organ systems of the human body. These receptors can be engaged with endogenous (e.g. anandamides) or exogenous

ligands (phytocannabinoids, other natural non-cannabis substances, and synthetic analogs of cannabinoids). Comparable

to many other therapeutic or technology platform areas of pharmacologic science, both naturally occurring substances

and new chemical entities (NCEs) are being developed via traditional drug development processes in an attempt to address

a plethora of different ailments. One such marketed product is Epidiolex® (highly purified cannabidiol, or CBD, by GW

Pharmaceuticals) which was FDA approved in June of 2018 for Dravet Syndrome, a rare and treatment resistant seizure

disorder usually diagnosed in children at age 2 or older. Other cannabinoid drug candidates are in development and we


will undoubtedly witness the arrival of more medicines from this category or better yet, if lucky enough, take part in

meaningfully improving the lives of the patients using this new arsenal in our field.

SESSION B

B-1: Current Progress on Protein Degradation Therapeutics

Hyunsun Jo, Ph.D.

CEO, Pin Therapeutics

Biography

Dr. Hyunsun Jo is an entrepreneur in the biopharmaceutical industry. He is currently a Founder and Chief Executive Officer

at Pin Therapeutics, which is located in South San Francisco and Korea. Pin Therapeutics is backed by many venture capitals

and actively developing integrative drug discovery platform at the field of protein degradation therapeutics using small

molecules. Prior to founding Pin Therapeutics, Dr. Jo has founded two biotech companies called by a LabQnA and an

Embedbio. He obtained his BA and PhD in Molecular Biology (Metabolic Diseases) at Seoul National University and Postdoc

(aging-related diseases) at the Gladstone Institute (UCSF).

Abstract

Pin Therapeutics is aiming at creating therapeutic products based on the monovalent (molecular glue) and bivalent

(PROTAC technology), which utilizes compounds to degrade target proteins within the cell. The typical antibody or small

molecule drug exerts its efficacy by binding to the target protein and inhibiting the function of the protein. Antibodies can

bind to only cell surface targets and are unable to bind to intracellular proteins. While small molecule inhibitors have been

effective with targets like kinase inhibitors, researchers are realizing that it is very difficult to inhibit many types of proteins

with small molecule inhibitors. The protein degradation therapeutics approach can allow us to target these proteins that

are currently considered undruggable. The protein degradation therapeutics can hijack the E3 ligase system and/or

lysosomal degradation to degrade target proteins. Over the last couple of years, the literature has demonstrated the

concept. Molecular glue concept has been approved as a drug. Moreover in vivo efficacy of PROTAC compounds have been

published by a few groups, strengthening the applicability and raising the clinical potential.

Pin Therapeutics is building in-house capability and a network of collaborator to develop protein degradation therapeutics

for basically disease-agnostic. Pin Therapeutics’s uniqueness is largely coming from two aspects: 1. Biological specificity

for target’s degradation hijacking unique E3 ligase complex. 2. Unique technologies that protein degradation therapeutics

can be efficiently developed and a variety of screening assays

B-2: Antisense Oligonucleotide Therapeutics for Difficult to Inhibit Drug Targets

Youngsoo Kim, Ph.D.

Director, Ionis Pharmaceuticals

Biography

Youngsoo Kim, Ph.D. is currently the Director of Oncology at Ionis (formerly known as, Isis) Pharmaceuticals Inc., a

biotechnology company with its focus on RNA-targeted therapy. He obtained his B.S. and M.S. degrees in Biology from

Seoul National University in Seoul, Korea and his doctoral degree from the University of Texas at Austin while working on

his research projects under Dr. Susan M. Fischer at the University of Texas MD Anderson Cancer Center. He joined Dr. John

C. Reed’s lab at the Burnham Institute (now, Sanford Burnham Prebys Medical Discovery Institute) for his postdoctoral

training in 1999, where he investigated the regulatory mechanisms of antiapoptotic proteins in tumor cells. He was the

recipients of Susan G. Komen Breast Cancer and California Breast Cancer Research Postdoctoral fellowships during his

training. He then joined Ionis Pharmaceuticals in 2002 as a senior scientist. Since then, he has been playing a leading role


in Ionis’ oncology drug discovery program by moving multiple next generation antisense oligonucleotides (ASOs) drugs

into clinical stages, which led to the successful establishment of broad partnerships with AstraZeneca and UT MD Anderson

Cancer Center for target discovery and clinical development for the treatment of highly refractory cancer to current

therapies. He currently serves as a JSC (joint steering committee) member of the Ionis-MDACC collaboration. He is also an

author of > 30 publications in high impact journals and an inventor of the therapeutic applications of multiple ASO targets

in cancer.

Abstract

Our increased understanding on human genome has led to the identification of key disease-causing genes. However, most

of potential drug targets are still intractable by conventional therapeutic approaches. In this regard, RNA-targeted

therapeutics largely represented by antisense oligonucleotides (ASOs) and siRNA have emerged as attractive therapeutic

modalities to overcome the limitation with their specificity and having RNA as their target molecule. Significant advances

made in RNA-targeted therapeutics have led to seven FDA-approved drugs for multiple indications thus far. In this

presentation, first I will provide a brief overview of RNA-targeted therapeutics with a focus on their key differences. Then,

I will cover the evolution of ASO technology, its wide range of mechanism of action, and recent clinical successes of several

drugs for non-oncology indications including SPINRAZA® for the treatment of spinal muscular atrophy (SMA). Finally, I will

present some of highlights from several preclinical and clinical programs Ionis and its partners have been advancing in

oncology, where significant antitumor effects have been observed by next generation (constrained ethyl=cEt) ASOs

targeted to different classes of oncogenic drivers. With these advances in technology, ASO drugs are now poised to be

used to intervene difficult-to-inhibit drug targets for the treatment of a variety of diseases including cancer.

B-3: Critical Ligand-Binding Reagents for Robust Bioanalytical Assays: Characterization and Lifecycle Management

Hanjo Lim, Ph.D.

Scientific Manager, Genentech

Biography

Dr. Hanjo Lim is an expert in analytical characterization of proteins and antibodies for more than 20 years. Dr. Lim is

currently Scientific Manager at BioAnalytical Sciences Department of Genentech since Jan. 2014, where he oversees and

enhances the processes of PK/ADA/PD assay reagent production/characterization/management for Genentech biologics

programs in development as well as influencing scientific directions and leading research activities related to the critical

assay reagents. Prior to joining Genentech, Dr. Lim worked at Sanofi for ~12 years as Principal Research Investigator in

proteomic drug target discovery and characterization of Sanofi biologics drug candidates and also briefly served as Mass

Spec Manager at a startup biosimilar company TPI in Chicago for 1 year. Dr. Lim obtained his BS and MS in Chemistry and

Organic Chemistry respectively from Seoul National University and Ph.D. in Analytical Chemistry (Mass Spectrometry) from

University of Illinois at Chicago.

Abstract

Ligand binding assays (LBAs) are used at almost all stages of the drug development process from discovery to post-

marketing monitoring and have been the industry gold standard bioanalytical methods for PK, PD, and immunogenicity

assessments of protein biologics in clinical trials. Critical reagents are essential components of LBAs whose unique

characteristics impact assay performance. Thus, effective management of the critical reagents is crucial not only to ensure

robust and consistent assay performance throughout the lifetime of the methods but also to minimize the costly delays of

project progression during drug development. Systematic physicochemical and biophysical characterization of these

critical reagents utilizing several key analytical antibody characterization tools including LC-MS and SEC-MALS plays an


important role in this regard by ensuring batch-to-batch consistency of each supply of the reagents as well as expediting

troubleshooting of the reagents when needed. This talk will discuss critical reagents associated with the key assays

(PK/PD/ADA) used in drug development and then show utility of a couple of key analytical tools that our group is employing

in reagent characterization and troubleshooting.

SATURDAY DINNER & PANEL DISCUSSION

"IND: Regulatory Path and Content"

Regulatory Affair – ‘IND’

Sandy Suh, Pharm.D., Regulatory Affairs, Exeltis

Biography

Sandy Suh is Head of Regulatory Affairs (R&D) at Exeltis USA, Inc. which is part of Insud Pharma. Insud is a global company

established over 40 years ago and provides active pharmaceutical ingredients, generics, biosimilars, and innovative

pharmaceutical products. Since joining the company in 2014, she completed 2 successful NDA approvals: treatment of a

rare disease (Chagas) and a progestin-only pill for female contraception. She maintains PINDs/INDs and has participated in

over 20 Regulatory Agency meetings (mostly with US FDA but also with EMA, MPA in Sweden, MEB in The Netherlands,

and ANMAT in Argentina). The prior 18 years were spent at companies including MannKind, Pfizer/Pharmacia, and Abbott.

She earned her B.S. and Doctor of Pharmacy degrees from the St. Louis College of Pharmacy (St. Louis, MO) and has been

a registered pharmacist since 1995.

Drug Metabolism and Pharmacokinetics (DMPK) Deliverables in Support of IND Filing

Mi-Sook Kim, Ph.D., DMPK, Takeda

Biography

Dr. Mi-Sook Kim is Principal Scientist at Takeda Pharmaceuticals in the department of Drug Metabolism and

Pharmacokinetics (DMPK) based in Boston. Since joining the Takeda in 2006, she has been representing DMPK department

in a cross-functional discovery taskforce, preclinical and clinical development teams in support of small and large molecule

oncology programs. Her primary responsibility at Takeda is to design, coordinate, analyze and interpret the results from

the PK and ADME studies and to contribute in the regulatory filing. Prior to joining Takeda, she supported various drug

discovery and development programs for therapeutic indications including diabetes, obesity, depression, rheumatoid

arthritis, glaucoma, and schizophrenia at the department of Drug Metabolism at Merck & Co., Rahway, NJ. She received

her B.S. in Pharmacy from Seoul National University, Seoul, Korea and obtained her Ph.D. in Biochemistry from Vanderbilt

University, Nashville, Tennessee.

Drug Safety Package to Enable IND Filing

Sean Kim, Ph.D., Quantitative Pharmacology and Drug Safety, Blueprint Medicines

Biography

Sean Kim is Senior Director of Quantitative Pharmacology and Drug Safety at Blueprint Medicines, which is specialized in

applying precision medicines approaches to kinase inhibitor for oncology and rare diseases. Prior to Blueprint, he spent

last 18 years in Bristol-Myers Squibb and Novartis as a safety and DMPK project leader across multiple therapeutic areas,

namely Oncology/IO, Ophthalmology, CNS and Infectious diseases. and multiple modalities, including small molecule, mAb,

SiRNA, anti-sense RNA and bi-specific Ab. He received his Ph.D. in Toxicology at Rutgers, The State of University of New

Jersey.


POSTER SESSION

AWARDEE ABSTRACTS

2019 SPRING FELLOWSHIP AWARDEES

AWARD NAME AWARDEE SCHOOL

KASBP–Hanmi Fellowship Seung Wook Kim University of Texas at Austin

KASBP–Hanmi Fellowship Kwang-Su Park Ichan School of Medicines at Mt. Sinai

KASBP–Hanmi Fellowship Jooman Park University of Massachusetts

KASBP–Yuhan Fellowship Hyunkyung Jung University of Illinois at Urbana Champaign

KASBP–Yuhan Fellowship Woosook Kim Columbia University

KASBP–Yuhan Fellowship Sungjoon Cho University of Illinois at Chicago

KASBP–GC Pharma Fellowship Hongsuk Park Washington University School of Medicines in St. Louis

KASBP–GC Pharma Fellowship Byungyong Ahn University of Pennsylvania

KASBP–SKBP Fellowship Jung Eun Paik Memorial Sloan Kettering Cancer Center

KASBP-SKBP Fellowship Jeongjoon Choi Yale University

P-1: Regio- and Enantioselective Amination of Branched Allylic Acetates Bearing Linear Alkyl Groups

Seung Wook Kim and Michael J. Krische

University of Texas at Austin, Department of Chemistry (A5300), AUSTIN, TX 78712-0165

E-mail: [email protected]

Transition metal-catalyzed allylic substitution has emerged as

a powerful method for stereoselective C-N bond formation.

Chiral iridium- phosphoramidite complexes have proven

especially effective as catalysts for regio- and enantioselective

allylic amination, but are limited to ARYL- substituted π-allyl

electrophiles. We have demonstrated that π- allyliridium C,O-

benzoate complexes catalyze completely regio- and highly

enantioselective aminations of diverse ALKYL-substituted

allylic electrophiles. Mechanistic studies corroborate C-N bond

formation via outer-sphere addition.

1 Meza, A. T.; Wurm, T.; Smith, L.; Kim, S. W.; Zbieg, J. R.; Stivala, C. E.; Krische, M. J. J. Am. Chem. Soc. 2018, 140, 1275.

2 Kim, S. W.; Schwartz, L. A.; Zbieg, J. R.; Stivala, C. E.; Krische, M. J. J. Am. Chem. Soc. 2019, 141, 671.

3 Kim, S. W.; Schempp, T. T.; Zbieg, J. R.; Stivala, C. E.; Krische, M. J. Angew. Chem. Int. Ed. 2019, Just Accepted.

P-2: Towards discovery of selective molecular probes detecting tau fibrils as non-invasive diagnosis tool for Alzheimer's

disease

Kwang-Su Park


Icahn School of Medicine at Mount Sinai, New York, USA

Email: [email protected]

Recently, age-related diseases such as Alzheimer’s disease (AD) have gained attention as a serious social problem. However,

there is no single diagnosis system to detect AD. In this context, many approaches to monitor the progression of AD at

early stage have been tried. Among them, near-infrared fluorescence (NIRF) imaging has been proposed as a promising

and non-invasive method to visualize the hallmarks of AD, amyloid β (Aβ) fibrils and aggregated tau, because of its

acceptable depth of penetration and minimal degree of tissue damage. In this study, we focused on the detection of

aggregated tau rather than Aβ fibrils by NIRF imaging because of the proven correlation between the amount of tau protein

load and cognitive impairment in AD patients. In order to develop an NIRF probe against aggregated tau, several known

NIRF probes detecting aggregated tau and Aβ fibrils such as [11C]-PBB3, CRANAD-2, DANIR-2c and MCAAD-3 gave us

perspective for designing molecules. Based on the structures of the characteristic donor-π-acceptor architecture of these

tau-specific probes, various modifications were attempted to optimize the fluorescent properties as well as the tau-

selectivity against Aβ fibrils. Collectively, several promising NIRF probes specifically staining aggregated tau have been

designed and synthesized and evaluated their abilities.

P-3: Role of Interleukn 33 (IL-33) in beige adipocytes

Jooman Park and Silvia Corvera

University of Massachusetts, Medical School, Suite 107, 373 Plantation St, Worcester, MA, USA 01605


Uncoupling protein 1 (UCP1) is the critical regulator of thermogenesis in BAT and “brite/beige” adipose tissue. Here we

identify to investigate a possible functional connection between UCP1 and interleukin 33 (IL 33). IL 33 deficiency mice

impeded browning in the cold-exposure stimulation and leads to a decrease the kinetic of Ucp1 mRNA and protein levels.

In addition, glucose and insulin sensitivity is impaired. Moreover, IL 33 expression is remarkably increased upon acute

stimulating forskolin (FSK) as well UCP1 expression in human beige adipocytes. Interestingly, IL 33 is abundance in nucleus

upon acute stimulating FSK. Upon chronic stimulating FSK, IL 33 is secreted. Furthermore, IL 33 overexpression in human

beige adipocytes increases UCP1 expression and protein levels by its secreted. These results reveal a role of IL 33 in

improving energy expenditure via regulating UCP1 protein and given that strengthens its validity as an anti-obesity target.

P-4: Photoacoustic-guided imaging and drug delivery to lung cancer targeted by a peptide probe in K-rasLA2 mutant

mice

Hyunkyung Jung1,2, Yu-Kyoung Oh4, In-San Kim5, Chulhong Kim3*, Byungheon Lee2*

1Department of Molecular & Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL 61801. 2CMRI,

School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu 41944, Republic of Korea.

3Departments of Creative IT Engineering and Electrical Engineering, Pohang University of Science and Technology, 77

Cheongam-Ro, Nam-Gu, Pohang, Gyeongbuk 37673, Republic of Korea. 4College of Pharmacy, Seoul National University, 1

Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea. 5Biomedical Center, Korea Institute of Science and Technology, 5

Hwarang-ro 14 gil, Seongbukgu, Seoul 02792, Republic of Korea.



The lack of molecular targets and targeting probes remains a major drawback in targeted imaging and drug delivery for

lung cancer. In this study, we exploited in vivo phage display to identify a novel targeting probe that homes to the tumor

in a K-rasLA2 mutant mouse lung cancer model. Compared with other candidate peptides selected from five rounds of

phage display, the CRQTKN peptide homed to tumor nodules in the lung of mutant mice at higher levels. Photoacoustic

tomography of mutant mice detected lung tumors via tumor homing of the nearinfrared fluorescence dye-labeled CRQTKN

peptide. Ex vivo photoacoustic images of isolated organs further demonstrated tumor homing of the CRQTKN peptide,

while minimal accumulation was observed in control organs, such as the liver. Compared with untargeted liposomes,

doxorubicin-loaded liposomes surface modified with the CRQTKN peptide more efficiently delivered doxorubicin and

reduced the number of tumor nodules measuring >3 mm in diameter. Affinity-based identification was used to detect

tumor necrosis factor receptor superfamily member 19L (TNFRSF19L), which was up-regulated in lung tumors of mutant

mice, as the receptor for the CRQTKN peptide. In conclusion, these results suggest that the CRQTKN peptide is a promising

targeting probe for photoacoustic-guided detection and drug delivery to lung cancer, and acts by binding to TNFRSF19L as

a novel molecular target.

P-5: PD-1/PD-L1 axis drives gastric tumorigenesis with tumor-infiltrating myeloid-derived suppressor cells

Woosook Kim, Timothy Chu, Henrik Nienhueser, Zhengyu Jiang, Yoku Hayakawa, James Fox, Charles Drake and Timothy

Wang

Department of Medicine, Columbia University Medical Center, 1130 St. Nicholas Avenue, Room 901, New York, NY 10032


Advanced gastric cancer is difficult to cure with chemotherapy or radiation therapy. Therefore, new therapeutic

approaches are clearly needed. Recent clinical studies of anti-PD-1 agents showed promising activity in a subset of gastric

cancer patients but the biological roles of PD-1/PD-L1 in gastric cancer have not been well elucidated. Here we evaluated

the efficacy of PD-1 blockade in mouse models of gastric cancer and examined the role of PD-L1 in gastric tumorigenesis.

Gastrin-deficient (GAS-KO) and H/K-APTase-IL-1b mice received Helicobacter felis and N-methyl-N-nitrosourea (MNU) to

induce large antral tumors and were treated with anti-PD-1 (mDX400, the murine analog against pembrolizumab) or

isotype antibody (10 mg/kg IP qw) in early and late treatment regimens. Tumors developed in GAS-KO are PD-L1+ and had

higher mutation rates than those in wild-type mice. GAS-KO receiving anti-PD-1 early exhibited a significant reduction in

tumor burden with increased CD8+ T cells and a remarkable decrease in myeloid-derived suppressor cells (MDSCs) within

the tumor. However, IL-1b mice showed resistance to anti-PD-1 despite increased T cell infiltration, which may due to a

high level of MDSCs recruited by constitutively secreted IL-1b from gastric parietal cells. Moreover, delayed anti-PD-1 did

not suppress growth of established tumors in GAS-KO and IL-1b mice with robust expansion of MDSCs in tumors.

Chemotherapy, 5-fluorouracil (30 mg/kg IP q2w) and oxaliplatin (5 mg/kg IP q2w), dramatically reduced MDSCs and

increased the response rate of gastric cancer to PD-1 blockade but caused PD-L1 overexpression on tumor cells mediating

immune evasion and resistance to checkpoint inhibition. To further explore the role of PD-L1 on gastric tumor and immune

cells, we generated knockin mice which conditionally express mouse Pdl1 gene. Tff2-Cre; R26-PD-L1 and LysM-Cre; R26-

PD-L1 mice expressed a high level of PD-L1 in the gastric epithelium and myeloid cell lineage, respectively. Overexpression

of PD-L1 on both gastric epithelial and myeloid cells markedly promoted tumor growth by MNU, which was accelerated by

Helicobacter infection. In contrast to LysM-Cre; R26-PD-L1 mice, Tff2-Cre; R26-PD-L1 mice showed higher tumor incidence


to MNU, implicating epithelial-derived PD-L1 increases susceptibility to carcinogen and accelerates tumor progression.

Upregulation of PD-L1 expression in myeloid cells facilitated tumor progression with enhanced suppression of CD8+ T cells.

These findings elucidate the interplay between growing tumors and immune system to evade anti-tumor activity.

Combinatorial treatments of PD-1 blockade with effective MDSC targeting are needed to further improve anti-tumor

efficiency in gastric cancer patients.

P-6: Commensal gut microbiota modulates susceptibility to acetaminophen-induced hepatotoxicity

Sungjoon Cho1, Kyoung-Jae Won2, Vanessa Leone4, Eugene B. Chang4, Hyunwoo Lee3, Hyunyoung Jeong1,2

1Department of Biopharmaceutical Sciences, 2Department of Pharmacy Practice, 3Department of Medicinal Chemistry and

Pharmacognosy, College of Pharmacy, University of Illinois at Chicago; 4Department of Medicine, University of Chicago,

Chicago, IL, USA


Overdose of acetaminophen (APAP) causes fulminant liver injury in humans. However, individual susceptibility to APAP-

induced liver toxicity (APAP toxicity) highly varies, and the risk factor(s) for the susceptibility remain unclear. In this study,

we explored a potential role of gut microbiota in modulating the susceptibility to APAP toxicity. C57BL/6 mice from two

different vendors [Jackson (JAX) and Taconic (TAC)] are known to have different gut microbiota. These conventional mice

were dosed with APAP (300 mg/kg, i.p), and alanine aminotransferase (ALT) levels in the serum (as a marker for liver injury)

were measured 24 h post-dosing. ALT activity in TAC mice was significantly higher than that in JAX mice. Interestingly, the

difference in APAP toxicity between JAX and TAC mice was abrogated when these mice were cohoused for 4 weeks and

treated with APAP (300 mg/kg, i.p). Moreover, germ-free C57BL/6 mice, when conventionalized with respective cecum

materials of JAX and TAC mice, exhibited similar APAP susceptibility patterns as seen with conventional JAX and TAC mice.

To determine the underlying mechanism of gut microbiota-mediated alteration in APAP toxicity, time course experiments

were performed using JAX and TAC mice. TAC mice exhibited faster and higher APAP-protein adduct level suggesting higher

metabolism of APAP to toxic reactive metabolite. The hepatic expression levels of CYP2E1 and CYP1A2, the major enzymes

mediating APAP bioactivation to a toxic metabolite, were similar between JAX and TAC mice. Hepatic concentrations of

APAP and APAP-GSH conjugate were also similar suggesting that APAP exposure and detoxification of toxic metabolite by

glutathione (GSH) were similar between JAX and TAC mice. Altogether, these data suggest that differential gut microbiota

modulate susceptibility to APAP toxicity potentially by altering metabolism of APAP to toxic metabolite which is not

mediated by altering CYP2E1 expression, hepatic APAP exposure and detoxification of toxic metabolite by GSH.

P-7: Role of Peroxisomes in Mitochondrial Dynamics and Adipose Tissue Thermogenesis

Hongsuk Park1, Anyuan He1, Min Tan1, Jordan M. Johnson2, John M. Dean1, Terri A. Pietka3, Yali Chen1, Xiangyu Zhang4,

Fong-Fu Hsu1, Babak Razani4, Katsuhiko Funai2, and Irfan J. Lodhi1*

1Division of Endocrinology, Metabolism and Lipid Research, Department of Medicine, Washington University School of

Medicine, Saint Louis, MO 63110, USA; 2Diabetes & Metabolism Research Center, University of Utah, Salt Lake City, UT

84112, USA; 3Nutrition and Geriatrics Division; 4Cardiology Division, Department of Medicine, Washington University

School of Medicine, Saint Louis, MO 63110, USA



Peroxisomes perform essential functions in lipid metabolism, including fatty acid oxidation and plasmalogen synthesis.

Here, we describe a role for peroxisomal lipid metabolism in mitochondrial dynamics in brown and beige adipocytes.

Adipose tissue peroxisomal biogenesis was induced in response to cold exposure through activation of the thermogenic

co-regulator PRDM16. Adipose-specific knockout of the peroxisomal biogenesis factor Pex16 impaired cold tolerance,

decreased energy expenditure, and increased diet-induced obesity. Pex16 deficiency blocked cold-induced mitochondrial

fission, decreased mitochondrial copy number, and caused mitochondrial dysfunction. Adipose-specific inactivation of

peroxisomal beta-oxidation was not sufficient to affect adiposity, thermogenesis or mitochondrial copy number, but

disruption of plasmalogen synthesis recapitulated the effects of Pex16 knockout on mitochondrial morphology.

Plasmalogens are present in mitochondria and decreased with Pex16 inactivation. Their dietary supplementation increased

mitochondrial copy number, improved mitochondrial function, and rescued thermogenesis in Pex16 knockout mice. These

findings support a surprising interaction between peroxisomes and mitochondria to regulate mitochondrial dynamics and

thermogenesis. Manipulating the production of peroxisome-derived lipids, plasmalogens, by dietary or pharmacological

means could improve the thermogenic feature of adipocytes as a promising strategy for treating metabolic syndrome.

P-8: MondoA Signaling Links Skeletal Muscle Lipid Accumulation and Insulin Resistance

Byungyong Ahn1 and Daniel P. Kelly1,2

1Cardiovascular Institute and 2Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of

Pennsylvania, Philadelphia, Pennsylvania 19104, USA


It is well known that insulin resistance in the obese state is associated with accumulation of neutral lipid in extra-adipose

tissues. This phenomenon is particularly well-documented in skeletal muscle. The mechanistic underpinnings of this

linkage are not fully understood. We hypothesized that fundamental homeostatic mechanisms exist to coordinately control

cellular lipid stores and insulin-mediated glucose uptake. Previously, using a small molecule phenotypic screen, we found

that the transcription factor MondoA inhibits muscle insulin signaling via activation of TXNIP (a known suppressor of insulin

signaling) and increases neutral lipid stores through an unknown mechanism. Current studies conducted in human skeletal

myotubes demonstrated that nutrient loading with glucose activated MondoA by triggering its localization to the nucleus.

Conversely, glucose starvation of myocytes led to nuclear exclusion of MondoA. Expression of TXNIP, and the related factor

ARRDC4, was regulated in accordance with nuclear levels of MondoA. These results indicated that in conditions of nutrient

(glucose) loading, MondoA serves to deactivate insulin signaling and reduce glucose uptake to prevent cellular nutrient

overload. Whole genome RNA-seq and ChIP-seq studies demonstrated that MondoA activates target genes involved in

nutrient storage pathways (TAG and glycogen synthesis) and insulin signaling. In addition, MondoA regulates KLF10 and

KLF11, known regulators of glucose homeostasis. Muscle-specific genetic deletion of MondoA in mice was shown to

improve glucose tolerance in the context of diet-induced obesity. We conclude that MondoA plays a key role as a cellular

transcriptional checkpoint to control nutrient catabolism by suppressing insulin signaling and shuttling fatty acids into

triglyceride stores during conditions of “plenty”. In the context of chronic activation of MondoA (caloric excess), a vicious

cycle of myocyte lipid accumulation and insulin resistance ensues. Accordingly, MondoA signaling is a candidate target for

strategies aimed at reducing insulin resistance and cellular lipotoxicity.


P-9: Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1

Jung Eun Baik, Mara Roxana Rubinstein, Yiping W Han

Division of Periodontics, College of Dental Medicine, Columbia University, New York, NY, USA


Fusobacterium nucleatum, a Gram-negative oral anaerobe, is a significant contributor to colorectal cancer. Using an in vitro

cancer progression model, we discover that F. nucleatum stimulates the growth of colorectal cancer cells without affecting

the pre-cancerous adenoma cells. Annexin A1, a previously unrecognized modulator of Wnt/β-catenin signaling, is a key

component through which F. nucleatum exerts its stimulatory effect. It is specifically expressed in proliferating colorectal

cancer cells and involved in activation of cyclin D1. Annexin A1 expression level in colon cancer is a predictor of poor

prognosis independent of cancer stage, grade, age and sex. The FadA adhesin from F. nucleatum up-regulates Annexin A1

expression through E-cadherin. A positive feedback loop between FadA and Annexin A1 is identified in the cancerous cells,

absent in the non-cancerous cells. We therefore propose a “two-hit” model in colorectal carcinogenesis, with somatic

mutation(s) as the first hit, and F. nucleatum as the second hit exacerbating cancer progression after benign cells become

cancerous. This model extends the “adenoma-carcinoma” model and identifies microbes such as F. nucleatum as cancer

“facilitators”.

P-10: How pathogens utilize their new genetic tools?

Jeongjoon Choi

Department of Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, USA


Horizontal gene transfer plays a critical role in bacterial evolution. Horizontally transferred genes often provide new

properties to an organism such as the utilization of carbon sources, resistance to antibiotics, and virulence. The heat-

stable nucleoid structuring (H-NS) protein silences transcription of foreign genes in a variety of Gram-negative bacterial

species. Because H-NS amounts are believed to remain constant, overcoming gene silencing has been largely ascribed to

DNA binding proteins that outcompete H-NS for binding to AT-rich foreign DNA or that form non-functional oligomers with

H-NS. We now report that the intracellular pathogen Salmonella enterica degrades H-NS when inside macrophages,

reducing H-NS amounts 16 fold. We identify Lon as the protease degrading H-NS, and show that Lon’s action lowers H-NS

binding to foreign DNA, thereby increasing the mRNA amounts of the corresponding genes. The DNA binding protein PhoP

promotes H-NS proteolysis by displacing H-NS from DNA, resulting in expression of foreign genes – even those whose

regulatory sequences are not bound by PhoP. The uncovered mechanism allows expression multiple foreign genes without

the need to evolve binding sites for anti-silencing proteins at each foreign gene. Our findings suggest that alteration of

foreign gene silencer could hamper bacterial pathogenesis.


PAST AWARDEES

KASBP-DAEWOONG ACHIEVEMENT

2009 Jong Eun KIM (Gilead Sciences, Inc.), (Kainos Medicine Inc, Korea, Current)

2010 David C. CHU, (University of Georgia)

2011 Sung Ho KIM (University of California, Berkeley)

2012 Dennis CHOI (Stony Brook Medicine and Stony Brook University)

2013 Joseph KIM (Inovio Pharmaceuticals)

2014 Kinam PARK (Purdue University)

2015 Jong Sung KOH (Genoscco)

2016 Jang-Ho CHA (Novartis)

2017 Peter PARK (Bicycle Therapeutics)

2018 Jong Wook LEE (Daewoong Pharmaceuticals)

KASBP RECOGNITION AWARD

2015 Jong Wook LEE (Daewoong)

KASBP-DAEWOONG FELLOWSHIP

2006 JaeKi MIN (New York University), Hahn KIM (Princeton University), HyeJin PARK (Rutgers University)

2007 JiSook MOON (Harvard University), SungYeon PARK (Rutgers University), SeokGeun LEE (Columbia

University)

2008 HeungKyu LEE (Yale University), JungHwan KIM (Rutgers University), MinSik KANG (Columbia University)

2009 JinAh PARK (Harvard University), JaeMin CHOI (Yale University), DeokHo KIM (Johns Hopkins University)

2010 JungMin KEE (Rockefeller University), HyungWook KIM (NIH), SeJin AHN (Harvard University)

2011 MooRi HAN (University of California, LA), HwanJong JANG (Boston College)

2012 JeongHo JANG (Columbia University), JaeWoo CHOI (Oregon State University)

2013 JangEun LEE (University of Pennsylvania), Eun Chan PARK (Rutgers University)

2014 Kimberly H. KIM (Harvard University), Seung Koo LEE (Weill Cornell Medical College), Min-Sik KIM (Johns

Hopkins University)

2015 Jiyeon KIM (UT Southwestern), Sun Mi PARK (Memorial Sloan-Kettering Center); Byeong Seon KIM

(University of Pennsylvania)

2016 Sang Bae LEE (Columbia University), Junil KIM (University of Pennsylvania), Ho-Keun KWON (Harvard

Medical School)

2017 KyeongJin KIM (Columbia University Medical Center), Min-Ji BAK (Ernest Mario School of Pharmacy),

Heung Sik HAHM (Free University Berlin)

2018 Jung Ho HYUN (Max-Planck Florida Institute for Neuroscience), Seung Hoon LEE (Harvard Medical

School), Jang Hwan CHO (Boston University)


KASBP-GC Pharma (formerly GREEN CROSS) FELLOWSHIP

2011 HanSang CHO (Harvard Medical School), SungWoong KANG (Johns Hopkins University), MiYeon KIM

(Columbia University), JaeYoung SOH (Rutgers University), SungYong HWANG (NIEHS/NIH)

2012 WonJin CHO (Drexel University), HyoJung KANG (Yale University), JungHyun LEE (Columbia University),

YongJae LEE (Yale University), JaeHyun YOON (NIH)

2013 Yunjong LEE (Johns Hopkins University), Jun-Dae KIM (Yale University), Bae-Hoon KIM (Yale University),

Ja Young KIM-MULLER (Columbia University)

2014 Catherine RHEE (University of Texas at Austin), Ji-Seon SEO (The Rockefeller University) Sehyun KIM (New

York University)

2015 Young-Su YI (New York University), Hee-Woong LIM (University of Pennsylvania), Bloria Bora KIM (The

Pennsylvania State University)

2016 Eui Tae KIM (University of Pennsylvania), Kihyun LEE (Weill Cornell Medical Science)

2017 Seung-Yeol PARK (Harvard medical school), Young Bok Abraham KANG (Harvard medical school)

2018 Jae Yeon HWANG (Yale University), Youngjin KIM (Rockefeller University)

KASBP-HANMI FELLOWSHIP

2011 HyungJin AHN (Rockefeller University), ChangHoon CHO (Abramson Research Center)

2012 YuNa KIM (University of North Carolina), HyunSeob TAE (Yale University), InHye LEE (NIH)

2013 JooHee LEE (Memorial Sloan-Kettering Cancer Center), KyungRyun LEE (Rutgers University), ManRyul LEE

(Indiana University)

2014 Young Chan CHA (Wistar Institute), Min-Kyu CHO (New York University), Lark Kyun KIM, (Yale University),

Yu Shin KIM (Johns Hopkins University)

2015 Seonil KIM (New York University), Peter B. KIM (Yale University)

2016 Sungwhan OH (Harvard Medical School), Won-Gil LEE (Yale University), Hee-Jin JEONG (Harvard Medical

School)

2017 Seungkyu LEE (Harvard Medical School), Soo Seok HWANG (Yale University), Heeoon HAN (University of

Pennsylvania)

2018 Jae Yeon HWANG (Yale University), Yeong Shin YIM (MIT), Dahea YU (Rutgers University)

KASBP-LG CHEM FELLOWSHIP

2017 Kyoung-Dong KIM (Wistar Institute), Seok-Man HO (Icahn School of Medicine at Mount Sinai)

2018 Kisa SUNG (Icahn School of Medicine at Mount Sinai), Gihoon LEE (University of Chicago)

KASBP-QURIENT FELLOWSHIP

2018 Soeun KANG (University of Illinois at Chicago), Do Hyung KIM (Johns Hopkins University)


KASBP-YUHAN FELLOWSHIP

2011 KiYoung KIM (Boston University), JoongSeop SHIM (Johns Hopkins University)

2012 YeMin HUH (University of Michigan), SookHee BANG (University of Pennsylvania), JungHo BAIK (Columbia

University)

2013 Dong Jun LEE (University of Chicago), Ingyu KIM (Yale University), Ja Yil LEE (Columbia University)

2014 Seouk Joon KWON (Rensselaer Polytech Institute), Jeongmin SONG (Yale University), Jae-Hyun YANG

(Harvard Medical School), Wan Seok YANG (Columbia University)

2015 Min-Joon HAN (Harvard Medical School), Minjung KANG (Cornell University)

2016 Ki Su KIM (Harvard Medical School), Hongjae SUNWOO (Harvard Medical School), Seo-Young PARK

(University of Massachusetts)

2017 Hanseul YANG (Rockefeller University), Ji-Hoon PARK (NIH), Hong-Yeoul RYU (Yale University)

2018 Sangdoo KIM (Harvard Medical School), Baehyun SHIN (Harvard Medical School), Mikyung YU (Harvard

Medical School)

KASBP-ST PHARM FELLOWSHIP

2016 Jung-Eun JANG (New York University), Byungsu KWON (MIT)

KASBP FELLOWSHIP

2009 SangHo CHOI (NIH)

2010 SangRyung KIM (Columbia University), TaeSook YOON (Rutgers University), EunMi HUH (Cal. Tech.)

2015 Mi Jung KIM (Duke University), Minyoung PARK (The Rockefeller University)

2018 Sinyoung JEONG (Harvard Medical School), Young Eun LEE (Monell Chemical Senses Center)

KASBP-KSEA FELLOWSHIP

2013 Sung In LIM (University of Virginia)

2014 Keun-woo JIN (Temple University)

KASBP-KUSCO FELLOWSHIP

2008 HyunHo KIM (National Institutes of Health), TaekBeom OHN (Harvard Medical School), WonAh JOO

(Wistar Institute)

KASBP-KRICT FELLOWSHIP

2009 SeungSik SHIN (Rutgers University), EunJoo JEONG (Columbia University), KyuWon BAEK (University of

Pennsylvania)

KASBP-KHIDI FELLOWSHIP

2010 JaeHyun BAE (Yale University), HeeYeon CHO (Boston College)


KASBP-DAEWOONG SCHOLARSHIP

2006 Jin K. PAI, Schering-Plough (Handok Pharmaceuticals, Korea, Current)

2007 YoungWhan PARK, Merck (National Cancer Center, Korea, Current)

2008 Young-Choon MOON (PTC Therapeutics)

2009 HongYong KIM (Novartis)


2019 KASBP Spring Symposium Attendees

Last name First name 한글 이름 Affiliation Group Networking

1. Ahn Byungyong 안병용 University of Pennsylvania

2. Ahn Kyonghoon 안경훈 Daewoong pharmaceutical company, Bio-research cencer

Immuno-oncology/Autoimmune/Inflammatory

3. Ahn Sungwoo 안성우 Yuhan USA BD/Legal/VC:

4. AN YOUNGTAE 안영태 DGMIF

5. Aoyagi Kazuko Celerion Inc Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

6. Bae Jihyun 배지현 Rutgers University Pharmacy

7. Baik Jungeun 백정은 Memorial Sloan Kettering Cancer Center

Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

8. Chang Kern 장건희 Janssen R&D LLC. Immuno-oncology/Autoimmune/Inflammatory

9. Chang Rae Sung 장래성 Access Bio, Inc. PK/PD/pre-clinical/Clinical Science:

10. Cho Jeong Woo 조정우 SK Biopharmaceuticals

11. CHO SUNG YUN 조성윤 Weill Cornell Medicine Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

12. Cho Sungjoon 조성준 University of Illinois at Chicago PK/PD/pre-clinical/Clinical Science:

13. Cho Woong Hee 조웅희 UT Southwestern Medical Center Cell and Gene Therapy/Viral infection/Rare disease

14. Cho Yong 조용성 YC Consulting BD/Legal/VC:

15. Choe Yun H. 최윤 Lucas and Mercanti, LLP BD/Legal/VC:

16. Choi Barlgum 최밝음 Alexion Pharmaceuticals Cell and Gene Therapy/Viral infection/Rare disease

17. Choi Jeea 최지아 Novartis Immuno-oncology/Autoimmune/Inflammatory

18. Choi Jeongjoon 최정준 Yale University Cell and Gene Therapy/Viral infection/Rare disease

19. Choi Junyong 최준용 Queens College - CUNY Chemistry

20. Choi Seungkwon 최승권 GC Pharma (GC녹십자)

21. Choi Yongjin 최용진 Regeneron Pharmaceuticals, Inc. BD/Legal/VC:

22. Choo Min-Kyung 추민경 Takeda Immuno-oncology/Autoimmune/Inflammatory

23. Chung DaEun 정다은 Rutgers University Pharmacy

24. Chung HaeWon 정해원 Asimov Cell and Gene Therapy/Viral infection/Rare disease

25. Chung Seung Wook 정승욱 Boehringer Ingelheim PK/PD/pre-clinical/Clinical Science:

26. Chung Seungwon 정승원 AbbVie Chemistry

27. HAHM Sean 함성원 The Yakup Shinmoon

28. Han Celine Garam 한가람 BMS (Bristol-Myers Squibb) Immuno-oncology/Autoimmune/Inflammatory

29. HAN DAE 한대엽 YALE UNIVERSITY

30. Han Wooseok 한우석 Novartis Institutes for BioMedical Research

Chemistry

31. Han Yong-Hae 한용해 CJ Healthcare Immuno-oncology/Autoimmune/Inflammatory

32. hong hyunryung NEW YORK BLOOD CENTER



33. Hong Miyoun Celgene Corp Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

34. Hong Patrick Cellectis Inc. Cell and Gene Therapy/Viral infection/Rare disease

35. Hwang Ji Young 황지영 Torque Therapeutics PK/PD/pre-clinical/Clinical Science:

36. Im Eunju 임은주 Nathan S. Kline Institute/NYU school of Medicine


37. JANG JAYOUNG 장자영 Weil cornell university Cell and Gene Therapy/Viral infection/Rare disease

38. JEONG Heykyeong 정혜경 Temple University Cell and Gene Therapy/Viral infection/Rare disease

39. Jeong Jae Uk 정재욱 GSK

40. Jeong Yu Young 정유영 Rutgers University Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

41. Jo Eui-Cheol 조의철 Mogam Institute for Biomedical Research

Cell and Gene Therapy/Viral infection/Rare disease

42. Jo Hakryul 조 학렬 Agios Pharmaceuticals Cell and Gene Therapy/Viral infection/Rare disease

43. Jo Jay-Hyun 조재현 NIH Immuno-oncology/Autoimmune/Inflammatory

44. Jo JIhye 조지혜 Yale Chemistry Department

45. Ju-Hyun Lim 임주현 Hanmi

46. Jung Hyunkyung 정현경 University of Illinois at Urbana Champaign

PK/PD/pre-clinical/Clinical Science:

47. Kam Emily Northeastern University

48. Kam Yoonseok 감윤석 Agilent Technologies Immuno-oncology/Autoimmune/Inflammatory

49. Kang hyekyung 강혜경 ChemicalEnergy Investment Management

BD/Legal/VC:

50. Kang Min-Jong 강민종 Yale University School of Medicine

51. Kim Boyoung 김보영 Harvard Medical School Cell and Gene Therapy/Viral infection/Rare disease

52. Kim Byungchan 김병찬 Schrodinger Inc Chemistry

53. Kim Dennis Kim Dong Won

Emerald Health Sciences Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

54. Kim Domyoung 김도명 RPI Cell and Gene Therapy/Viral infection/Rare disease

55. Kim Gloria 김보라 University of Pennsylania Cell and Gene Therapy/Viral infection/Rare disease

56. Kim Huen Suk (Crystal)

김현숙 MSKCC Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

57. Kim Hyaeyeong 김혜영 Weill Cornell Medicine Cell and Gene Therapy/Viral infection/Rare disease

58. Kim Hyelim MCPHS University Cell and Gene Therapy/Viral infection/Rare disease

59. Kim Hyun Chung 김현정 KSEA Pharmacy

60. Kim Hyunjin Rutgers University Pharmacy

61. Kim Hyunjin 김현진 CKD Pharmaceuticals Chemistry

62. Kim HyunJun 김현준 MCPHS University Pharmacy

63. Kim Ilhoon 김일훈 GC녹십자 Cell and Gene Therapy/Viral infection/Rare disease

64. Kim Jae-Hun 김재훈 IFF Chemistry



65. Kim Jia 김지아 Weill Cornell Medicine Cell and Gene Therapy/Viral infection/Rare disease

66. Kim Jinhee 김진희 Rutgers New Jersey Medical School


67. Kim Jinrang 김진랑 Regeneron Pharmaceuticals

68. Kim John Pierre Fabre Pharmaceuticals, Inc.

BD/Legal/VC:

69. Kim Joohae 김주혜 St. John’s University BD/Legal/VC:

70. Kim Joonyul 김준열 Proximity Biosciences Inc BD/Legal/VC:

71. Kim Juny 김주은 CRScube America BD/Legal/VC:

72. Kim Kevin 김재훈 Wave Life Sciences Cell and Gene Therapy/Viral infection/Rare disease

73. Kim Kyung 김경효 AbbVie

74. Kim Minsu 김민수 VORONOI Inc. Immuno-oncology/Autoimmune/Inflammatory

75. Kim Mi-Sook 김미숙 Takeda PK/PD/pre-clinical/Clinical Science:

76. Kim Nam Cheol 김남철 United States Pharmacopeia Pharmacy

77. Kim Sahee 김사희 RevHealth Pharmacy

78. Kim Sanghyeon 김상현 SMRI Immuno-oncology/Autoimmune/Inflammatory

79. Kim Sarah 김별 St.John’s University Pharmacy

80. Kim Sean 김승빈 Blueprint Medicines PK/PD/pre-clinical/Clinical Science:

81. Kim Seong Kon 김성곤 종근당 Chemistry

82. Kim Seung Wook 김승욱 University of Texas at Austin Chemistry

83. Kim Seungkee 김승기 Ernest Mario School of Pharmacy Pharmacy

84. Kim Soan 김소안 Albany College of Pharmacy and Health Sciences

Pharmacy

85. Kim Sung ki 김성기 MCPHS university BD/Legal/VC:

86. Kim Sung-jun 김성준 the yakup shinmoon

87. Kim Sung-Kwon 김성권 Alexion Pharmaceuticals Immuno-oncology/Autoimmune/Inflammatory

88. Kim Woosook 김우숙 Columbia University Medical Center


89. Kim Young Woo 김 영우 Access Bio BD/Legal/VC:

90. Kim Youngsoo 김영수 Ionis Pharmaceuticals Inc. Immuno-oncology/Autoimmune/Inflammatory

91. Kim Youngsun 김영선 Adello Biologics Cell and Gene Therapy/Viral infection/Rare disease

92. Kong Philip 공필립 Yale University PK/PD/pre-clinical/Clinical Science:

93. Koo Jaseok Yale School of Medicine

94. kwon hyuk-kwon 권혁권 1Department of Orthopaedics and Rehabilitation, Yale University School of Medicine

95. KWON ICK CHAN 권익찬 Dana Farber Cancer Institute Immuno-oncology/Autoimmune/Inflammatory

96. Kwon Keon Woo 권건우 University of Pennsylvania Cell and Gene Therapy/Viral infection/Rare disease

97. Kwon Ohbong 권오봉 New York City College of Technology

98. Kwon Se Chang 권세창 Hanmi



99. Laramy Janice 이경미 SK Life Science

100. Lee Boeun 이보은 University of Pennsylvania Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

101. Lee Chang-Sun (Sam)

이창선 Legochem Bio

102. Lee Dong Min (Janet)

이동민 Novocure Pharmacy

103. Lee Dooyoung 이두영 Morphic Therapeutic PK/PD/pre-clinical/Clinical Science:

104. Lee Gwen 이귀인 PRISMS BD/Legal/VC:

105. Lee Hak-Myung 이학명 Shire Cell and Gene Therapy/Viral infection/Rare disease

106. Lee Hyun-Hee 이현회 Merck Immuno-oncology/Autoimmune/Inflammatory

107. LEE INKYU 이인규 Yale medical school Orthoperdics and Rehabilitation

108. Lee Inyoung 이인영 University of Illinois at Chicago (UIC)

BD/Legal/VC:

109. Lee Ji Eun 이지은 MCPHS University Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

110. Lee Kyuhong 이규홍 Korea Institute of Toxicology Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

111. Lee Lauren Young-Mi

이영미 한미약품

112. Lee Saelim 이세림 Orthopaedics&rehabilitation department, Yale medical school

113. Lee SJ 이승주 Orum Therapeutics Immuno-oncology/Autoimmune/Inflammatory

114. Lee So Jeong 이소정 Rutgers University, Ernest Mario School Of Pharmacy

Pharmacy

115. Lee SungKyoung 이성경 University of Pennsylvania and Jubilee Biotech

PK/PD/pre-clinical/Clinical Science:

116. Lee Yong-Hee 이용희 Bridge Biotherapeutics US

117. LEE YOUNKYOUNG

이윤경 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH


118. Lim Hanjo 임한조 Genentech PK/PD/pre-clinical/Clinical Science:

119. Lim Jihyeon 임지현 Johnson and Johnson Chemistry

120. MIN SANGHYUN 민상현 DGMIF

121. Min Sooweon University of Illinois at Chicago College of Pharmacy

122. Moon Dawn 문다은 Northeastern University Pharmacy

123. Moon JaeHoon 문재훈 (주)녹십자 종합연구소

124. Moon Young-Choon 문영춘 PTC Therapeutics, Inc.

125. NA Seungtaek 나승택 DAEJOONG Investment Co. Immuno-oncology/Autoimmune/Inflammatory

126. Nam Jongmin 남종민 Rutgers University-Camden BD/Legal/VC:

127. Oh Choongseob 오충섭 Celltrion

128. Oh Chris Chigon 오치곤 ENVIGO CRS KOREA BD/Legal/VC:

129. Oh Richard Novo Nordisk Pharmacy

130. Oh Seo Jin 오서진 St. John's University College of Pharmacy

Pharmacy

131. Oh Seung Wook 오승욱 MDimune Inc. Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative



132. Oh Younghoon 오영훈 Spark Therapeutics Cell and Gene Therapy/Viral infection/Rare disease

133. Paik Ik-Hyeon 백익현 WAVE Life Sciences, Inc. Chemistry

134. Park Hongsuk 박홍석 Washington University School of Medicine in St. Louis


135. Park Ji Young 박지영 Golden HealthCare Pharmacy PK/PD/pre-clinical/Clinical Science:

136. Park Jonghanne 박종한 LaSante Health Center PK/PD/pre-clinical/Clinical Science:

137. Park Jooman 박주만 University of Massachusetts Medical School


138. Park Joon Seok 박준석 대웅제약 Immuno-oncology/Autoimmune/Inflammatory

139. Park Kwangsu 박광수 School of medicine at Mount Sinai

Chemistry

140. Park Kyo 박기효 GC Pharma (GC녹십자)

141. Park Melody 박나슬 MCPHS University Pharmacy

142. Park Saejeong 박세정 Yale University Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

143. PARK SANGWOOK 박상욱 대원제약 PK/PD/pre-clinical/Clinical Science:

144. Park Soo-Hee 박수희 Novartis Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

145. Park Soyeon 박소연 한미약 품

146. Park Sungyong 박성용 IPON Boston, Inc. BD/Legal/VC:

147. PARK YOOHOI 박유회 Yuhan R&D Institute Immuno-oncology/Autoimmune/Inflammatory

148. Rhee So Hyun 이소현 Rutgers University PK/PD/pre-clinical/Clinical Science:

149. Rhu Hong Yeol 류홍열 Yale University Chemistry

150. RYOO JEPHIL 류제필 Galaxy Bio Inc. Immuno-oncology/Autoimmune/Inflammatory

151. Seo Jiwon 서지원 Northeastern University Pharmacy School

BD/Legal/VC:

152. SHIN HYEON JUN 신현준 Yale School of Medicine

153. Shin Young Eun 신영은 St. John's University Pharmacy

154. Sohn Jung-woo 손정우 ATCC Center for Translational Microbiology

155. SOHN SEIL 손세일 대원제약(주) PK/PD/pre-clinical/Clinical Science:

156. Son Jimin 손지민 St. John's University BD/Legal/VC:

157. Son MinYoung NewYork-Presbyterian Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

158. SON MOONHO 손문호 DGMIF

159. Song Dongweon 송동원 Pfizer

160. Song Mina 송민아 N/A Cell and Gene Therapy/Viral infection/Rare disease

161. Song Saera 송세라 Columbia University Cell and Gene Therapy/Viral infection/Rare disease

162. Song Yvonne Ehwang

송이황 Sanofi Pharmacy

163. Suh K. Stephen 서광선 DiagnoCine Cell and Gene Therapy/Viral infection/Rare disease

164. Suh Sandy Exeltis Pharmacy

165. Sung Kisa 성기사 Icahn School of Medicine at Mount Sinai




166. Sung Moo Je 성무제 Novartis Chemistry

167. UH DONGKYU 어동규 Daewoong Pharmaceuticals BD/Legal/VC:

168. Um Moonkyoung 엄문경 Mintz Levin BD/Legal/VC:

169. woo changjae 우창재 국립암센터 Pharmacy

170. Woo Jungreem 우정림 Thomas Jefferson University Cell and Gene Therapy/Viral infection/Rare disease

171. Yang Hyeon Jeong 양현정 Rutgers University Pharmacy student

Pharmacy

172. Yang Sungjae 양성재 CELLTRION

173. Yang Yerin 양예린 St. John's University Pharmacy

174. Yi Sooji 이수지 Northeastern University Pharmacy

175. Yoo Lang 유랑 Nathan Kline Institute Respiratory/metabolic/cardiovascular/Aging/mental/Neurogenerative

176. Yoon Taewon 윤태원 유한 USA (Boston office) Immuno-oncology/Autoimmune/Inflammatory

177. Yoon Taeyoung 윤태영 Dong-A ST Immuno-oncology/Autoimmune/Inflammatory

Group Networking Last name First name 한글 이름 Affiliation

Ahn Byungyong 안병용 University of Pennsylvania

AN YOUNGTAE 안영태 DGMIF

Cho Jeong Woo 조정우 SK Biopharmaceuticals

Choi Seungkwon 최승권 GC Pharma (GC녹십자)

HAHM Sean 함성원 The Yakup Shinmoon

HAN DAE 한대엽 YALE UNIVERSITY

hong hyunryung NEW YORK BLOOD CENTER

Jeong Jae Uk 정재욱 GSK

Jo JIhye 조지혜 Yale Chemistry Department

Ju-Hyun Lim 임주현 Hanmi

Kam Emily Northeastern University

Kang Min-Jong 강민종 Yale University School of Medicine

Kim Jinrang 김진랑 Regeneron Pharmaceuticals

Kim Kyung 김경효 AbbVie

Kim Sung-jun 김성준 the yakup shinmoon

Koo Jaseok Yale School of Medicine

kwon hyuk-kwon 권혁권 1Department of Orthopaedics and Rehabilitation, Yale University School of Medicine

Kwon Ohbong 권오봉 New York City College of Technology

Kwon Se Chang 권세창 Hanmi

Laramy Janice 이경미 SK Life Science

Lee Chang-Sun (Sam)

이창선 Legochem Bio

LEE INKYU 이인규 Yale medical school Orthoperdics and Rehabilitation



Lee Lauren Young-Mi

이영미 한미약품

Lee Saelim 이세림 Orthopaedics&rehabilitation department, Yale medical school

Lee Yong-Hee 이용희 Bridge Biotherapeutics US

MIN SANGHYUN 민상현 DGMIF

Min Sooweon University of Illinois at Chicago College of Pharmacy

Moon JaeHoon 문재훈 (주)녹십자 종합연구소

Moon Young-Choon 문영춘 PTC Therapeutics, Inc.

Oh Choongseob 오충섭 Celltrion

Park Kyo 박기효 GC Pharma (GC녹십자)

Park Soyeon 박소연 한미약 품

SHIN HYEON JUN 신현준 Yale School of Medicine

Sohn Jung-woo 손정우 ATCC Center for Translational Microbiology

SON MOONHO 손문호 DGMIF

Song Dongweon 송동원 Pfizer

Yang Sungjae 양성재 CELLTRION

BD/Legal/VC: Ahn Sungwoo 안성우 Yuhan USA

BD/Legal/VC: Cho Yong 조용성 YC Consulting

BD/Legal/VC: Choe Yun H. 최윤 Lucas and Mercanti, LLP

BD/Legal/VC: Choi Yongjin 최용진 Regeneron Pharmaceuticals, Inc.

BD/Legal/VC: Kang hyekyung 강혜경 ChemicalEnergy Investment Management

BD/Legal/VC: Kim John Pierre Fabre Pharmaceuticals, Inc.

BD/Legal/VC: Kim Joohae 김주혜 St. John’s University

BD/Legal/VC: Kim Joonyul 김준열 Proximity Biosciences Inc

BD/Legal/VC: Kim Juny 김주은 CRScube America

BD/Legal/VC: Kim Sung ki 김성기 MCPHS university

BD/Legal/VC: Kim Young Woo 김 영우 Access Bio

BD/Legal/VC: Lee Gwen 이귀인 PRISMS

BD/Legal/VC: Lee Inyoung 이인영 University of Illinois at Chicago (UIC)

BD/Legal/VC: Nam Jongmin 남종민 Rutgers University-Camden

BD/Legal/VC: Oh Chris Chigon 오치곤 ENVIGO CRS KOREA

BD/Legal/VC: Park Sungyong 박성용 IPON Boston, Inc.

BD/Legal/VC: Seo Jiwon 서지원 Northeastern University Pharmacy School

BD/Legal/VC: Son Jimin 손지민 St. John's University

BD/Legal/VC: UH DONGKYU 어동규 Daewoong Pharmaceuticals

BD/Legal/VC: Um Moonkyoung 엄문경 Mintz Levin


Cho Woong Hee 조웅희 UT Southwestern Medical Center


Choi Barlgum 최밝음 Alexion Pharmaceuticals


Choi Jeongjoon 최정준 Yale University




Chung HaeWon 정해원 Asimov


Hong Patrick Cellectis Inc.


JANG JAYOUNG 장자영 Weil cornell university


JEONG Heykyeong 정혜경 Temple University


Jo Eui-Cheol 조의철 Mogam Institute for Biomedical Research


Jo Hakryul 조 학렬 Agios Pharmaceuticals


Kim Boyoung 김보영 Harvard Medical School


Kim Domyoung 김도명 RPI


Kim Gloria 김보라 University of Pennsylania


Kim Hyaeyeong 김혜영 Weill Cornell Medicine


Kim Hyelim MCPHS University


Kim Ilhoon 김일훈 GC녹십자


Kim Jia 김지아 Weill Cornell Medicine


Kim Kevin 김재훈 Wave Life Sciences


Kim Youngsun 김영선 Adello Biologics


Kwon Keon Woo 권건우 University of Pennsylvania


Lee Hak-Myung 이학명 Shire


LEE YOUNKYOUNG

이윤경 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH


Oh Younghoon 오영훈 Spark Therapeutics


Song Mina 송민아 N/A


Song Saera 송세라 Columbia University


Suh K. Stephen Kwangsun Suh

DiagnoCine


Sung Kisa 성기사 Icahn School of Medicine at Mount Sinai


Woo Jungreem 우정림 Thomas Jefferson University

Chemistry Choi Junyong 최준용 Queens College - CUNY

Chemistry Chung Seungwon 정승원 AbbVie

Chemistry Han Wooseok 한우석 Novartis Institutes for BioMedical Research

Chemistry Kim Byungchan 김병찬 Schrodinger Inc

Chemistry Kim Hyunjin 김현진 CKD Pharmaceuticals

Chemistry Kim Jae-Hun 김재훈 IFF



Chemistry Kim Seong Kon 김성곤 종근당

Chemistry Kim Seung Wook 김승욱 University of Texas at Austin

Chemistry Lim Jihyeon 임지현 Johnson and Johnson

Chemistry Paik Ik-Hyeon 백익현 WAVE Life Sciences, Inc.

Chemistry Park Kwangsu 박광수 School of medicine at Mount Sinai

Chemistry Rhu Hong Yeol 류홍열 Yale University

Chemistry Sung Moo Je 성무제 Novartis


Ahn Kyonghoon 안경훈 Daewoong pharmaceutical company, Bio-research cencer


Chang Kern 장건희 Janssen R&D LLC.


Choi Jeea 최지아 Novartis


Choo Min-Kyung 추민경 Takeda


Han Celine Garam 한가람 BMS (Bristol-Myers Squibb)


Han Yong-Hae 한용해 CJ Healthcare


Jo Jay-Hyun 조재현 NIH


Kam Yoonseok 감윤석 Agilent Technologies


Kim Jinhee 김진희 Rutgers New Jersey Medical School


Kim Minsu 김민수 VORONOI Inc.


Kim Sanghyeon 김상현 SMRI


Kim Sung-Kwon 김성권 Alexion Pharmaceuticals


Kim Woosook 김우숙 Columbia University Medical Center


Kim Youngsoo 김영수 Ionis Pharmaceuticals Inc.


KWON ICK CHAN 권익찬 Dana Farber Cancer Institute


Lee Hyun-Hee 이현회 Merck


Lee SJ 이승주 Orum Therapeutics


NA Seungtaek 나승택 DAEJOONG Investment Co.


Park Joon Seok 박준석 대웅제약


PARK YOOHOI 박유회 Yuhan R&D Institute


RYOO JEPHIL 류제필 Galaxy Bio Inc.


Yoon Taewon 윤태원 유한 USA (Boston office)


Yoon Taeyoung 윤태영 Dong-A ST

Pharmacy Bae Jihyun 배지현 Rutgers University



Pharmacy Chung DaEun 정다은 Rutgers University

Pharmacy Kim Hyun Chung 김현정 KSEA

Pharmacy Kim Hyunjin Rutgers University

Pharmacy Kim HyunJun 김현준 MCPHS University

Pharmacy Kim Nam Cheol 김남철 United States Pharmacopeia

Pharmacy Kim Sahee 김사희 RevHealth

Pharmacy Kim Sarah 김별 St.John’s University

Pharmacy Kim Seungkee 김승기 Ernest Mario School of Pharmacy

Pharmacy Kim Soan 김소안 Albany College of Pharmacy and Health Sciences

Pharmacy Lee Dong Min (Janet)

이동민 Novocure

Pharmacy Lee So Jeong 이소정 Rutgers University, Ernest Mario School Of Pharmacy

Pharmacy Moon Dawn 문다은 Northeastern University

Pharmacy Oh Richard Novo Nordisk

Pharmacy Oh Seo Jin 오서진 St. John's University College of Pharmacy

Pharmacy Park Melody 박나슬 MCPHS University

Pharmacy Shin Young Eun 신영은 St. John's University

Pharmacy Song Yvonne Ehwang

송이황 Sanofi

Pharmacy Suh Sandy Exeltis

Pharmacy woo changjae 우창재 국립암센터

Pharmacy Yang Hyeon Jeong 양현정 Rutgers University Pharmacy student

Pharmacy Yang Yerin 양예린 St. John's University

Pharmacy Yi Sooji 이수지 Northeastern University

PK/PD/pre-clinical/Clinical Science: Chang Rae Sung 장래성 Access Bio, Inc.

PK/PD/pre-clinical/Clinical Science: Cho Sungjoon 조성준 University of Illinois at Chicago

PK/PD/pre-clinical/Clinical Science: Chung Seung Wook 정승욱 Boehringer Ingelheim

PK/PD/pre-clinical/Clinical Science: Hwang Ji Young 황지영 Torque Therapeutics

PK/PD/pre-clinical/Clinical Science: Jung Hyunkyung 정현경 University of Illinois at Urbana Champaign

PK/PD/pre-clinical/Clinical Science: Kim Mi-Sook 김미숙 Takeda

PK/PD/pre-clinical/Clinical Science: Kim Sean 김승빈 Blueprint Medicines

PK/PD/pre-clinical/Clinical Science: Kong Philip 공필립 Yale University

PK/PD/pre-clinical/Clinical Science: Lee Dooyoung 이두영 Morphic Therapeutic

PK/PD/pre-clinical/Clinical Science: Lee SungKyoung 이성경 University of Pennsylvania and Jubilee Biotech

PK/PD/pre-clinical/Clinical Science: Lim Hanjo 임한조 Genentech

PK/PD/pre-clinical/Clinical Science: Park Ji Young JiYoung Park

Golden HealthCare Pharmacy

PK/PD/pre-clinical/Clinical Science: Park Jonghanne 박종한 LaSante Health Center

PK/PD/pre-clinical/Clinical Science: PARK SANGWOOK 박상욱 대원제약

PK/PD/pre-clinical/Clinical Science: Rhee So Hyun 이소현 Rutgers University

PK/PD/pre-clinical/Clinical Science: SOHN SEIL 손세일 대원제약(주)


Aoyagi Kazuko Celerion Inc




Baik Jungeun 백정은 Memorial Sloan Kettering Cancer Center


CHO SUNG YUN 조성윤 Weill Cornell Medicine


Hong Miyoun Celgene Corp


Im Eunju 임은주 Nathan S. Kline Institute/NYU school of Medicine


Jeong Yu Young 정유영 Rutgers University


Kim Dennis Kim Dong Won

Emerald Health Sciences


Kim Huen Suk (Crystal)

김현숙 MSKCC


Lee Boeun 이보은 University of Pennsylvania


Lee Ji Eun 이지은 MCPHS University


Lee Kyuhong 이규홍 Korea Institute of Toxicology


Oh Seung Wook 오승욱 MDimune Inc.


Park Hongsuk 박홍석 Washington University School of Medicine in St. Louis


Park Jooman 박주만 University of Massachusetts Medical School


Park Saejeong 박세정 Yale University


Park Soo-Hee 박수희 Novartis


Son MinYoung NewYork-Presbyterian


Yoo Lang 유랑 Nathan Kline Institute

KASBP Spring Symposium Sponsors

page 2019 kasbp spring symposium spring symposium/20… · president sean kim 김승빈 lueprint...

Documents